A Phase 3 interventional study of GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 11 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-08.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 19th largest by enrollment, is the only one that started in 2017, is one of 22 in phase 3, and was the 20th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 1 started in 2017.
This study's enrollment of 404 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 22nd largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2017, is one of 25 in phase 3, and was the 31st registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age
The study will evaluate the impact of HZ/su vaccination on the QoL, 400 adults ≥ 50 years of age (YOA). Subjects will be asked to respond to a series of SF-36 and EQ-5D questionnaires before and after vaccination following a 2 month schedule. To estimate the impact of reactogenicity on an individual's physical functioning (PF) and QoL, the study will compare subject questionnaire responses made during two periods, i.e., pre-vaccination and post-vaccination. The difference will be considered to be the effect of vaccination and reactogenicity on the PF and QoL. To characterize the study population and determine if frailty may influence reactogenicity and consequently the impact on QoL scores, the subjects' frailty status will be assessed at the first inclusion visit. In addition to the SF-36 and EQ-5D questionnaires, a more complete characterization of the reactogenicity of the vaccine will be made by including a detailed collection of the use of healthcare resources and the occurrence of symptoms through diary card data collection. Impact on days of work loss, both for the subject or for a caregiver, as applicable, will also be assessed.
Note that as a result of internal change in data standards terminology, the study data collected was converted to cDISC and the statistical analysis plan was amended accordingly. "Day 0" in the study design was replaced by "Day 1"; consequently, "Day n" was replaced by "Day n+1". Thus, the timeframes (Day 0, Day n) of Outcome Measures described in this study record are different to that denoted in the full protocol document posted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Drug page: Shingrix
2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose
Descriptive analysis of the mean and standard deviation (SD) of the change from baseline of the SF-36 physical functioning (PF) score pre- and post dose 1 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
Time frame: From Baseline at Day -7 to Day 8 after first dose
Change in Mean SF-36 PF Scale Scores From Baseline Score to Mean Score After Second Dose
Descriptive analysis of the mean and standard deviation of the change from baseline of the SF-36 PF scale score pre and post dose 2 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (Day 1 for dose 2). The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Change in Mean SF-36 PF Single Item Scores After First Dose
Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after the first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.
Time frame: From Baseline at Day -7 to Day 8 after first dose
Change in Mean SF-36 PF Single Item Scores After Second Dose
Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Baseline versus mean score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.
Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Change in SF-36 Role Physical Scores After First Dose
Descriptive analysis. SF-36 Role physical scores change was measured from baseline score. Baseline versus mean score on Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
Time frame: From Baseline at Day -7 to Day 8 after first dose
Change in SF-36 Role Physical Scores After Second Dose
Descriptive analysis. SF-36 Role Physical scores change was measured from baseline score. Changes in the score were measured as Baseline versus Day 8 score after the second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Change in Quality-adjusted Life Year (QALY) After First Dose
Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are used to generate the EQ-5D index utility score. The EQ-5D index utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome.
Time frame: From Baseline at Day -7 to Day 8 after first dose
Change in QALY After Second Dose
Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 and EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles (e.g. 1-no problem/no symptom) and profiles are subsequently converted to a continuous single index utility score (higher scores represent a better quality of life).
Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Number of Reactogenicity-triggered Medically Attended Visits After First Dose
Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.
Time frame: From Day 1 to Day 7 after first dose
Number of Reactogenicity-triggered Medically Attended Visits After Second Dose
Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.
Time frame: From Day 1 to Day 7 after second dose
Days of Work Loss for Subjects After First Dose
Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.
Time frame: From Day 1 to Day 7 after first dose
Days of Work Loss for Subjects After Second Dose
Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.
Time frame: From Day 1 to Day 7 after second dose
Days of Work Loss for Non-dedicated Caregivers After First Dose
Descriptive analysis. Estimation of work loss of non-dedicated caregivers expressed in days.Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers
Time frame: From Day 1 to Day 7 after first dose
Days of Work Loss for Non-dedicated Caregivers After Second Dose
Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for non-dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers
Time frame: From Day 1 to Day 7 after second dose
Days of Extra Work for Dedicated Caregivers After First Dose
Descriptive analysis. Estimation of extra work for dedicated caregivers. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers
Time frame: From Day 1 to Day 7 after first dose
Days of Extra Work for Dedicated Caregivers After Second Dose
Descriptive analysis. Estimation of extra work for dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers
Time frame: From Day 1 to Day 7 after second dose
Number of Subjects With Any and Grade 3 Solicited Local Symptoms After First Dose
Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling =erythema/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Second Dose
Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling=erythema/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Number of Days With Solicited Local Symptoms After First Dose
Assessed solicited local symptoms were pain, erythema and swelling.
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Number of Days With Solicited Local Symptoms After Second Dose
Assessed solicited local symptoms were pain, erythema and swelling.
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After First Dose
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal everyday activities. Grade 3 temperature=temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After Second Dose
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary, tympanic temperature ≥ 37.5 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Number of Days With Solicited General Symptoms After First Dose
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Number of Days With Solicited General Symptoms After Second Dose
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].
Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During a 30-day follow-up period (Day 1 to Day 30) after any vaccination (across doses).
Number of Subjects With Any and Related Serious Adverse Events (SAEs) During the Entire Study Period
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 1 to study end at Month 14
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From Day 1 to study end at Month 14
| Milestone | GSK1437173A Group |
|---|---|
| Started | 401 |
| Completed | 387 |
| Not completed | 14 |
| Withdrew: Withdrawal based on medical judgement | 1 |
| Withdrew: Lost to follow-up | 8 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Adverse event | 2 |
Descriptive analysis of the mean and standard deviation (SD) of the change from baseline of the SF-36 physical functioning (PF) score pre- and post dose 1 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
| Score units | GSK1437173A Group |
|---|---|
| Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose | 1.9 ± 10.44 |
Descriptive analysis of the mean and standard deviation of the change from baseline of the SF-36 PF scale score pre and post dose 2 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (Day 1 for dose 2). The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
| Score units | GSK1437173A Group |
|---|---|
| Change in Mean SF-36 PF Scale Scores From Baseline Score to Mean Score After Second Dose | -0.4 ± 10.38 |
Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after the first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.
| Score units | GSK1437173A Group |
|---|---|
| Vigorous activites | 6.8 ± 26.26 |
| Moderate activites | 1.5 ± 16.76 |
| Lifting or carrying groceries | 1.5 ± 13.84 |
| Climbing several flights | 0.7 ± 17.77 |
| Climbing one flight | 0.5 ± 16.26 |
| Bending, kneeling or stooping | 5.8 ± 19.86 |
| Walking more than a mile | -0.2 ± 19.28 |
| Walking several hundred yards | -0.1 ± 16.66 |
| Walking one hundred yards | 1.8 ± 15.11 |
| Bathing or dressing himself/herself | 0.9 ± 11.35 |
Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Baseline versus mean score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.
| Score units | GSK1437173A Group |
|---|---|
| Vigorous activities | 2.6 ± 22.58 |
| Moderate activities | -1.2 ± 16.82 |
| Carrying groceries | -0.2 ± 13.05 |
| Climbing several flights | -3.7 ± 18.76 |
| Climbing one flight | -1.6 ± 16.09 |
| Bending or kneeling | 3.9 ± 19.32 |
| Walking more than mile | -2.3 ± 17.77 |
| Walking several 100 yards | -2.0 ± 15.30 |
| Walking 100 Yards | -0.1 ± 13.48 |
| Bathing/dressing self | 1.0 ± 12.01 |
Descriptive analysis. SF-36 Role physical scores change was measured from baseline score. Baseline versus mean score on Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
| Score units | GSK1437173A Group |
|---|---|
| Change in SF-36 Role Physical Scores After First Dose | 1.4 ± 14.97 |
Descriptive analysis. SF-36 Role Physical scores change was measured from baseline score. Changes in the score were measured as Baseline versus Day 8 score after the second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.
| Score units | GSK1437173A Group |
|---|---|
| Change in SF-36 Role Physical Scores After Second Dose | -1.8 ± 16.40 |
Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are used to generate the EQ-5D index utility score. The EQ-5D index utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome.
| Score units | GSK1437173A Group |
|---|---|
| Change in Quality-adjusted Life Year (QALY) After First Dose | 0.1829 ± 0.55551 |
Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 and EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles (e.g. 1-no problem/no symptom) and profiles are subsequently converted to a continuous single index utility score (higher scores represent a better quality of life).
| Score units | GSK1437173A Group |
|---|---|
| Change in QALY After Second Dose | 0.1128 ± 0.52000 |
Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.
| Visits | GSK1437173A Group |
|---|---|
| Attended by Telephone Call | 2 |
| Attended by General Practicioner | 1 |
| Attended by Specialist | 0 |
| Attended by Emergency Room | 0 |
| Attended by Hospitalization | 0 |
Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.
| Visits | GSK1437173A Group |
|---|---|
| Attended by Telephone Call | 4 |
| Attended by General Practitioner | 1 |
| Attended by Specialist | 0 |
| Attended by Emergency Room | 0 |
| Attended by Hospitalization | 0 |
Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.
| Days | GSK1437173A Group |
|---|---|
| Days of Work Loss for Subjects After First Dose | 1.3 ± 1.0 |
Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.
| Days | GSK1437173A Group |
|---|---|
| Days of Work Loss for Subjects After Second Dose | 1.1 ± 0.4 |
Descriptive analysis. Estimation of work loss of non-dedicated caregivers expressed in days.Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers
No measurements were reported for this outcome.
Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for non-dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers
No measurements were reported for this outcome.
Descriptive analysis. Estimation of extra work for dedicated caregivers. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers
No measurements were reported for this outcome.
Descriptive analysis. Estimation of extra work for dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers
No measurements were reported for this outcome.
Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling =erythema/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group |
|---|---|
| Any Pain | 310 |
| Grade 3 Pain | 16 |
| Any Erythema | 92 |
| Grade 3 Erythema | 6 |
| Any Swelling | 53 |
| Grade 3 swelling | 3 |
Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling=erythema/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group |
|---|---|
| Any Erythema | 87 |
| Grade 3 Erythema | 7 |
| Any Pain | 292 |
| Grade 3 Pain | 21 |
| Any Swelling | 54 |
| Grade 3 Swelling | 3 |
Assessed solicited local symptoms were pain, erythema and swelling.
| Days | GSK1437173A Group |
|---|---|
| Pain | 3 (2 to 4) |
| Erythema | 2 (2 to 4) |
| Swelling | 2 (2 to 4) |
Assessed solicited local symptoms were pain, erythema and swelling.
| Days | GSK1437173A Group |
|---|---|
| Pain | 2.5 (2 to 3) |
| Erythema | 3.0 (2 to 4) |
| Swelling | 3.0 (1 to 4) |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal everyday activities. Grade 3 temperature=temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group |
|---|---|
| Any Fatigue | 134 |
| Grade 3 Fatigue | 13 |
| Related Fatigue | 120 |
| Any Gastrointestinal symptoms | 53 |
| Grade 3 Gastrointestinal symptoms | 4 |
| Related Gastrointestinal symptoms | 40 |
| Any Headache | 113 |
| Grade 3 Headache | 11 |
| Related Headache | 98 |
| Any Myalgia | 107 |
| Grade 3 Myalgia | 8 |
| Related Myalgia | 100 |
| Any Shivering | 50 |
| Grade 3 Shivering | 3 |
| Related Shivering | 48 |
| Any Temperature (oral route) | 37 |
| Grade 3 Temperature(≥39.0 °C) | 0 |
| Related Temperature | 34 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary, tympanic temperature ≥ 37.5 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group |
|---|---|
| Any Fatigue | 180 |
| Grade 3 Fatigue | 27 |
| Related Fatigue | 172 |
| Any Gastrointestinal symptoms | 53 |
| Grade 3 Gastrointestinal symptoms | 4 |
| Related Gastrointestinal symptoms | 44 |
| Any Headache | 146 |
| Grade 3 Headache | 11 |
| Related Headache | 127 |
| Any Myalgia | 128 |
| Grade 3 Myalgia | 16 |
| Related Myalgia | 121 |
| Any Shivering | 97 |
| Grade 3 Shivering | 14 |
| Related Shivering | 86 |
| Any Temperature (oral route) | 69 |
| Grade 3 Temperature(≥39.0 °C) | 1 |
| Related Temperature | 64 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].
| Days | GSK1437173A Group |
|---|---|
| Fatigue | 2 (1 to 3) |
| Gastrointestinal symptoms | 1 (1 to 3) |
| Headache | 2 (1 to 3) |
| Myalgia | 2 (1 to 3) |
| Shivering | 1 (1 to 2) |
| Temperature | 1 (1 to 2) |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].
| Days | GSK1437173A Group |
|---|---|
| Fatigue | 2.0 (1 to 3) |
| Gastrointestinal symptoms | 2.0 (1 to 3) |
| Headache | 1.5 (1 to 2) |
| Myalgia | 2.0 (1 to 3) |
| Shivering | 1.0 (1 to 2) |
| Temperature | 1.0 (1 to 1) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group |
|---|---|
| Any unsolicited adverse event | 127 |
| Grade 3 unsolicited adverse events | 25 |
| Related unsolicited adverse events | 29 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | GSK1437173A Group |
|---|---|
| Any SAEs | 14 |
| Related SAEs | 0 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | GSK1437173A Group |
|---|---|
| Any pIMDs | 2 |
| Related pIMDs | 0 |
Collected over Solicited local and general adverse events: Day 1 to 7 after each vaccination. Unsolicited adverse events: From Day 1-30 after each vaccination. SAEs: From Day 1 to study completion (month 14).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 2/401 (0.5%) | 14/401 (3.5%) | 370/401 (92.3%) |
| Event | GSK1437173A Group |
|---|---|
| Aortic valve stenosisCardiac disorders | 1/401 |
| Atrial fibrillationCardiac disorders | 1/401 |
| Atrioventricular block completeCardiac disorders | 1/401 |
| CardiomyopathyCardiac disorders | 1/401 |
| Coronary artery diseaseCardiac disorders | 1/401 |
| Stress cardiomyopathyCardiac disorders | 1/401 |
| ColitisGastrointestinal disorders | 1/401 |
| Large intestine perforationGastrointestinal disorders | 1/401 |
| DiverticulitisInfections and infestations | 1/401 |
| PneumoniaInfections and infestations | 1/401 |
| Event | GSK1437173A Group |
|---|---|
| Injection site painGeneral disorders | 341/401 |
| FatigueGeneral disorders | 227/401 |
| HeadacheNervous system disorders | 189/401 |
| MyalgiaMusculoskeletal and connective tissue disorders | 169/401 |
| injection site erythemaGeneral disorders | 125/401 |
| ChillsGeneral disorders | 115/401 |
| Gastrointestinal disorderGastrointestinal disorders | 88/401 |
| PyrexiaGeneral disorders | 88/401 |
| Injection site swellingGeneral disorders | 78/401 |
| NasopharyngithisInfections and infestations | 10/401 |
| Age, Continuous(Years) | GSK1437173A Group |
|---|---|
| Mean | 64.6 ± 8.8 |
| Sex: Female, Male(Participants) | GSK1437173A Group |
|---|---|
| Female | 235 |
| Male | 166 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group |
|---|---|
| African Heritage/African American | 48 |
| American Indian or Alaskan Native | 7 |
| Asian - East Asian Heritage | 2 |
| Asian - South East Asian Heritage | 1 |
| Other | 4 |
| White - Arabic / North African Heritage | 7 |
| White - Caucasian / European Heritage | 332 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Apr 2017, 2 months.
Results were first posted in Oct 2018, 1 year 6 months after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 2 months is below that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix